Kazia Therapeutics Stock Forecast
NASDAQ: KZIAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
KZIA analyst consensus
Consensus (6 analysts)
none
Avg. price target
$28.26+216.46%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Kazia Therapeutics (2026-10-09), 6 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $28.26, with a high estimate of $39.09 and a low estimate of $17.43. The average target implies upside of 216.5% from the current price of $8.93.
The spread between the highest and lowest targets is 124.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for KZIA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 33% |
| Buy | 4 | 67% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $17.43 | +95.18% |
| Average target | $28.26 | +216.46% |
| High target | $39.09 | +337.74% |